A New Era in Precision Medicine
American Thoracic Society 2016 International Conference Abstracts
Held May 13-18, 2016 in San Francisco, California 2012;130(2):332-342.e10.
A critical evaluation of anti-IL-13 and anti-IL-4 strategies in severe asthma.
Bagnasco D, et al. Int Arch Allergy Immunol. 2016;170(2):122-131.
Lebrikizumab treatment in adults with asthma.
Corren J et al. N Engl J Med. 2011;365(12):1088-1098.
An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications.
Dweik RA, et al. Am J Respir Crit Care Med. 2011;184(5):602–615.
Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds:a secondary analysis of the DREAM and MENSA studies.
Ortega HG, et al. Lancet Respir Med. 2016;4(7):549–556.
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
Wenzel S, et al. Lancet. 2016;388(10039):31-44.
Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study.
Chipps BE, et al. J Allergy Clin Immunol. 2012;130(2):332-342.e10.
Biologics in asthma—the next step toward personalized treatment.
Darveaux J, Busse WW. J Allergy Clin Immunol Pract. 2015;3(2):152-161.
Adult asthma biomarkers.
Kim MA, et al. Curr Opin Allergy Clin Immunol. 2014;14(1):49-54.
Mepolizumab treatment in patients with severe eosinophilic asthma
Ortega HG, et al. N Engl J Med. 2015;371(13):1198-1207.
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.
Castro M, et al. Lancet Respir Med. 2015;3(5):355-366.
Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
Brightling CE, et al. Lancet Respir Med. 2015;3(9):692-701.
Dupilumab in persistent asthma with elevated eosinophil levels.
Wenzel S, et al. N Engl J Med. 2013;368(26):2455-2466.
Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma.
Wechsler ME, et al. J Allergy Clin Immunol. 2013;132(6):1295-302.e3.
Global Strategy for Asthma Management and Prevention
Global Initiative for Asthma (GINA) 2016.
ERS/ATS: International guidelines on definition, evaluation, and treatment of severe asthma
Chung KF, et al. Eur Respir J. 2014;43(2):343-373.
American Academy of Allergy, Asthma, and Immunology (AAAAI)
The American Academy of Allergy, Asthma & Immunology is dedicated to the advancement of the knowledge and practice management of allergy, asthma, and immunology for optimal patient care.
Asthma and Allergy Foundation of America (AAFA)
AAFA is dedicated to improving the quality of life for people with asthma and allergic diseases through education, advocacy, and research.
American College of Allergy, Asthma & Immunology (ACAAI)
The ACAAI fosters a culture of collaboration and congeniality in which members work toward the common goals of patient care, education, advocacy, and research.
American College of Chest Physicians (CHEST Foundation)
The mission of CHEST Foundation is to develop resources to champion the prevention, diagnosis, and treatment of chest diseases through education, communication, and research.
American Lung Association
The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy, and research.
American Thoracic Society
The mission of the ATS is to improve health worldwide by advancing research, clinical care, and public health in respiratory disease, critical illness, and sleep disorders.
Clinical Assessment Tools
Asthma Control Test™ (ACT)
This 5-question test evaluates asthma control over the past 4 weeks on a 5-point Likert scale. A score of <20 on the ACT suggests asthma that is uncontrolled. Nathan RA, et al. J Allergy Clin Immunol. 2004;113(1):59-65.
Asthma Control Questionnaire (ACQ)
This 7-question assessment tool measures asthma control over the past 7 days. Six questions are self-administered by the patient, and 1 question requires a clinician’s input. Scores range from 1 (totally controlled) to 6 (severely uncontrolled. Juniper EF, et al. The Euro Respir J. 1999;14(4):902-907.
Asthma Therapy Assessment Questionnaire© (ATAQ)
This 4-question test assesses asthma control over the past 4 weeks. Each question has a possible score of 0 or 1; if the sum of the 4 question scores is >1, the patient’s asthma may be uncontrolled. Vollmer WM, et al. Am J Crit Care Med. 1999;160(5 Pt 1):1647-1652.